Repeated Amiodarone Dosing In Cardiac surgicaL Procedures — RADICAL  

Atrial Fibrillation Clinical Trial

Official title: Repeated Amiodarone Dosing In Cardiac surgicaL Procedures

Status Terminated

Clinical Trial Summary

This study is a single-center, prospective, randomized, open-label trial of subjects who develop atrial fibrillation after non-emergent cardiac surgery at the University of Kentucky Chandler Medical Center (UKCMC). Patients will be randomized to receive either a conventional amiodarone dosing regimen (CDR) or a repeated amiodarone bolus dosing regimen (RBDR).

Clinical Trial Description

This study will screen and consent approximately 150 patients undergoing non-emergent cardiac surgery. Approximately 60 of these patients are likely to develop stable postoperative atrial fibrillation (POAF) in the postoperative period. Amiodarone is commonly given as an initial intravenous (IV) bolus (150 mg IV) followed by a combined IV and oral load to a total dose of 8 gm. Because of amiodarone's beta-blocker activity, the IV bolus in patients with POAF is associated with a reduced heart rate that may lead to restoration of NSR. For this reason, some clinicians will provide up to 5 additional IV amiodarone boluses during the drug's loading period to treat RVR. ;

Related Conditions & MeSH terms

• Atrial Fibrillation

• NCT number: NCT05004077
• Study type: Interventional
• Source: University of Kentucky
• Status: Terminated
• Phase: Phase 4
• Start date: November 2, 2021
• Completion date: October 10, 2022